Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention
20 mai 2024 08h00 HE
|
Cerevance
BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced that Craig Thompson, chief...
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
09 mai 2024 08h00 HE
|
Cerevance
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will present an oral presentation at the...
Cerevance Achieves First Milestone in Research Collaboration with Merck
02 mai 2024 08h30 HE
|
Cerevance
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced the achievement of the first...
Cerevance to Participate at Upcoming Investor Conferences
29 avr. 2024 08h30 HE
|
Cerevance
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that company management will...
Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline
25 avr. 2024 08h00 HE
|
Cerevance
Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others Proceeds will advance Cerevance’s first-in-class...
Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
22 avr. 2024 08h30 HE
|
Cerevance
BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that the peer-reviewed...
Cerevance Presents at 35th Symposium on Medicinal Chemistry in Eastern England
17 avr. 2024 08h30 HE
|
Cerevance
BOSTON, April 17, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to deliver an oral...
Cerevance to Participate at the 23rd Annual Needham Virtual Health Care Conference
02 avr. 2024 08h30 HE
|
Cerevance
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced participation at the...
Cerevance Announces Presentation at Alzheimer’s Research UK Conference
13 mars 2024 08h30 HE
|
Cerevance
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a...
Cerevance Announces Presentation at AD/PD™ 2024 International Conference
27 févr. 2024 08h30 HE
|
Cerevance
BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a...